Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy

Freedman, Murray MD1; Kaunitz, Andrew M. MD2; Reape, Kathleen Z. MD3; Hait, Howard MS3; Shu, Haibin MS3

doi: 10.1097/gme.0b013e318199e734

Objective: The aim of this study was to evaluate low-dose synthetic conjugated estrogens A (SCE-A) cream administered twice weekly for the treatment of moderate to severe vulvovaginal atrophy (VVA) in a symptomatic postmenopausal population.

Methods: In a multicenter, double-blind, randomized, placebo-controlled study, 305 women with symptoms of VVA were treated with either 1 g SCE-A cream (n = 150) or matching placebo (n = 155) for a period of up to 12 weeks. Participants had to have a vaginal pH of greater than 5, less than or equal to 5% superficial cells on a vaginal smear, and at least one of five symptoms of VVA (dryness, soreness, irritation, pain with intercourse, and bleeding after intercourse) that was moderate or severe in intensity. Women had to select one moderate or severe symptom as the most bothersome.

Results: Efficacy was assessed at 2, 3, 4, 8, and 12 weeks and included the change from baseline in the severity of the most bothersome symptom (MBS), maturation index, and pH. Most women identified vaginal dryness as the MBS (48%) followed by pain with intercourse (31.3%). A statistically significant increase in the maturation index and significant decreases in pH and severity of the MBS were observed for those treated with SCE-A vaginal cream compared with placebo.

Conclusions: A low dose (1 g = 0.625 mg) of SCE-A vaginal cream administered twice weekly was shown to be effective compared with placebo in treating VVA in postmenopausal women for the three coprimary efficacy measures of maturation index, pH, and severity of the MBS.

A low-dose synthetic conjugated estrogens vaginal cream administered twice weekly was shown to be effective for the treatment of moderate to severe symptoms of vulvovaginal atrophy, including dyspareunia and vaginal dryness.

From the 1Department of Obstetrics and Gynecology, Medical College of Georgia, Augusta, GA; 2Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL; and 3Duramed Research, Inc., Bala Cynwyd, PA.

Received November 18, 2008; revised and accepted December 22, 2008.

Some of the data contained in this article were accepted in abstract form and presented as a poster at the American College of Obstetricians and Gynecologists Annual Clinical Meeting, New Orleans, LA, May 2008.

Funding/support: This study was supported by Duramed Pharmaceuticals, Inc.

Financial disclosure/conflicts of interest: Dr. Reape, Mr. Hait, and Mr. Shu are all full-time employees of Duramed Research, Inc.

Address correspondence to: Kathleen Z. Reape, MD, Duramed Research, Inc., One Belmont Avenue, Suite 1100, Bala Cynwyd, PA 19004. E-mail:

©2009The North American Menopause Society